See more : Inaba Denki Sangyo Co.,Ltd. (9934.T) Income Statement Analysis – Financial Results
Complete financial analysis of Schrödinger, Inc. (SDGR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Schrödinger, Inc., a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
- Foncière 7 investissement Société Anonyme (LEBL.PA) Income Statement Analysis – Financial Results
- Sundaram Finance Limited (SUNDARMFIN.NS) Income Statement Analysis – Financial Results
- Centuri Holdings, Inc. (CTRI) Income Statement Analysis – Financial Results
- Numinus Wellness Inc. (NUMIF) Income Statement Analysis – Financial Results
- Alibaba Group Holding Limited (89988.HK) Income Statement Analysis – Financial Results
Schrödinger, Inc. (SDGR)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://www.schrodinger.com
About Schrödinger, Inc.
Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 216.67M | 180.96M | 137.93M | 108.10M | 85.54M | 66.64M | 55.69M |
| Cost of Revenue | 75.97M | 79.93M | 72.31M | 44.62M | 36.45M | 23.70M | 15.89M |
| Gross Profit | 140.69M | 101.02M | 65.62M | 63.47M | 49.09M | 42.94M | 39.80M |
| Gross Profit Ratio | 64.93% | 55.83% | 47.57% | 58.72% | 57.39% | 64.43% | 71.46% |
| Research & Development | 181.77M | 126.37M | 90.90M | 64.70M | 39.40M | 34.52M | 27.67M |
| General & Administrative | 99.15M | 90.83M | 64.01M | 41.90M | 27.04M | 18.55M | 14.44M |
| Selling & Marketing | 37.23M | 30.64M | 22.15M | 17.80M | 21.36M | 17.83M | 16.72M |
| SG&A | 136.37M | 121.47M | 86.16M | 59.69M | 48.40M | 36.38M | 31.15M |
| Other Expenses | 0.00 | 3.95M | 1.06M | 2.25M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 318.14M | 247.84M | 177.06M | 124.39M | 87.81M | 70.91M | 58.82M |
| Cost & Expenses | 394.11M | 327.77M | 249.37M | 169.01M | 124.26M | 94.61M | 74.71M |
| Interest Income | 0.00 | 3.95M | 1.06M | 2.25M | 1.88M | 433.00K | 359.00K |
| Interest Expense | 0.00 | 3.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 5.55M | 4.34M | 2.85M | 3.66M | 3.64M | 2.89M | 1.69M |
| EBITDA | -171.90M | -142.47M | -108.60M | -57.26M | -35.08M | -25.08M | -17.34M |
| EBITDA Ratio | -79.34% | -80.01% | -86.97% | -79.12% | -52.60% | -36.41% | -28.18% |
| Operating Income | -177.45M | -149.12M | -111.44M | -60.92M | -38.72M | -27.97M | -19.02M |
| Operating Income Ratio | -81.90% | -82.41% | -80.80% | -56.35% | -45.26% | -41.97% | -34.15% |
| Total Other Income/Expenses | 220.37M | -2.31M | 10.64M | 34.62M | 12.74M | -379.00K | 1.96M |
| Income Before Tax | 42.92M | -149.13M | -100.81M | -26.29M | -25.97M | -28.35M | -17.06M |
| Income Before Tax Ratio | 19.81% | -82.41% | -73.09% | -24.32% | -30.36% | -42.54% | -30.63% |
| Income Tax Expense | 2.20M | 63.00K | 411.00K | 345.00K | -291.00K | 77.00K | 332.00K |
| Net Income | 40.72M | -149.19M | -101.22M | -26.64M | -25.68M | -28.43M | -17.39M |
| Net Income Ratio | 18.79% | -82.45% | -73.38% | -24.64% | -30.02% | -42.66% | -31.23% |
| EPS | 0.57 | -2.10 | -1.43 | -0.44 | -0.41 | -0.59 | -0.43 |
| EPS Diluted | 0.54 | -2.10 | -1.43 | -0.44 | -0.41 | -0.59 | -0.43 |
| Weighted Avg Shares Out | 71.78M | 71.17M | 70.59M | 60.02M | 63.27M | 48.47M | 40.38M |
| Weighted Avg Shares Out (Dil) | 74.99M | 71.17M | 70.59M | 60.02M | 63.27M | 48.47M | 40.38M |
Schrödinger Broadens and Accelerates Predictive Toxicology Initiative
Schrodinger price target raised to $28 from $27 at Goldman Sachs
Schrödinger (SDGR) Q3 2024 Earnings Call Transcript
Schrodinger, Inc. (SDGR) Reports Q3 Loss, Misses Revenue Estimates
Schrödinger Reports Third Quarter 2024 Financial Results
Schrödinger Announces Multi-Target Collaboration and Expanded Software Licensing Agreement with Novartis
Schrödinger Presents SGR-3515 Preclinical Data at 2024 EORTC-NCI-AACR Symposium
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Kuehn Law Encourages Investors of Schrodinger, Inc. to Contact Law Firm
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Source: https://incomestatements.info
Category: Stock Reports